Flagship Harbor Advisors’s Rein Therapeutics RNTX Stock Holding History

Flagship Harbor Advisors’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-25	Closed	–	–	1834
2020 Q3	$0	Hold	25	–	–	﹤0.01%	2190
2020 Q2	$0	Hold	25	–	–	﹤0.01%	2176
2020 Q1	$0	Hold	25	–	–	﹤0.01%	1993
2019 Q4	$0	Hold	25	–	–	﹤0.01%	1969
2019 Q3	$0	Hold	25	–	–	﹤0.01%	1985
2019 Q2	$0	Hold	25	–	–	﹤0.01%	1995
2019 Q1	$0	Hold	25	–	–	﹤0.01%	1972
2018 Q4	$0	Hold	25	–	–	﹤0.01%	2130
2018 Q3	$1K	Buy	25 +15	+150%	+$1.01K	﹤0.01%	2033
2018 Q2	$1K	Buy	+10	New	+$1.13K	﹤0.01%	1979

Other funds holding RNTX

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AIIC

AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

GPFA

Game Plan Financial Advisors Westlake, Ohio $222M AUM 22.82% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Flagship Harbor Advisors's RNTX Position: Q4 2020 in Review

Flagship Harbor Advisors sold out of Rein Therapeutics (RNTX) in Q4 2020, closing a stake of 25 shares.

Flagship Harbor Advisors first reported a position in RNTX in Q2 2018 and held it in 10 quarters. The position peaked at $1K in Q3 2018. 30 funds tracked by Wall St. Rank hold RNTX as of Q4 2020.

Flagship Harbor Advisors reported no remaining Rein Therapeutics position as of Q4 2020 after selling out during the quarter.
Flagship Harbor Advisors sold 25 Rein Therapeutics shares in Q4 2020.
Flagship Harbor Advisors first reported a position in Rein Therapeutics in Q2 2018 and held it in 10 quarters.
Flagship Harbor Advisors's Rein Therapeutics position peaked at $1K in Q3 2018.
30 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2020.

Based on Flagship Harbor Advisors's 13F filing for Q4 2020, filed 8 Feb 2021.